March Industry News.
作者信息
McCartney Fiona
机构信息
Research Scientist, University College Dublin, Dublin 4, D04 V1W8, Ireland.
出版信息
Ther Deliv. 2024;15(8):561-566. doi: 10.1080/20415990.2024.2365621. Epub 2024 Jun 28.
Abstract
摘要
相似文献
1
March Industry News.
Ther Deliv. 2024;15(8):561-566. doi: 10.1080/20415990.2024.2365621. Epub 2024 Jun 28.
2
Biotech news from around the world.
Nat Biotechnol. 2024 Sep;42(9):1330. doi: 10.1038/s41587-024-02396-9.
3
Biotech news from around the world.
Nat Biotechnol. 2024 Aug;42(8):1166. doi: 10.1038/s41587-024-02362-5.
4
COVID has shown the power of science-industry collaboration.
Nature. 2021 Jun;594(7863):302. doi: 10.1038/d41586-021-01580-0.
5
Vaccine news, March 2, 2000.
AIDS Treat News. 2000 Mar 17(339):5.
6
Free licensing of vaccines to end the COVID-19 crisis.
Lancet. 2021 Apr 3;397(10281):1261-1262. doi: 10.1016/S0140-6736(21)00467-0. Epub 2021 Mar 18.
7
Why Do We Still Lack a COVID-19 Vaccine? Searching for the Missing Pieces.
Endocr Metab Immune Disord Drug Targets. 2021;21(4):567-568. doi: 10.2174/1871530320666201207234914.
8
Ethical and Scientific Considerations Regarding the Early Approval and Deployment of a COVID-19 Vaccine.
Ann Intern Med. 2021 Feb;174(2):258-260. doi: 10.7326/M20-7357. Epub 2020 Nov 20.
9
Industry news update covering June 2021.
Ther Deliv. 2021 Oct;12(10):685-691. doi: 10.4155/tde-2021-0063. Epub 2021 Sep 27.
10
Is there light at the end of the Covid-19 tunnel?
Rev Med Virol. 2021 May;31(3):e2173. doi: 10.1002/rmv.2173. Epub 2020 Oct 1.
本文引用的文献
1
Danicopan: First Approval.
Drugs. 2024 May;84(5):613-618. doi: 10.1007/s40265-024-02023-6. Epub 2024 Mar 26.
2
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.
3
Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial.
Lancet Haematol. 2023 Dec;10(12):e955-e965. doi: 10.1016/S2352-3026(23)00315-0.
4
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.
5
FLOW trial stopped early due to evidence of renal protection with semaglutide.
Eur Heart J Cardiovasc Pharmacother. 2024 Jan 5;10(1):7-9. doi: 10.1093/ehjcvp/pvad080.
6
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.
Nephrol Dial Transplant. 2023 Aug 31;38(9):2041-2051. doi: 10.1093/ndt/gfad009.
7
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.
Lancet. 2022 Dec 3;400(10367):1927-1937. doi: 10.1016/S0140-6736(22)02034-7. Epub 2022 Nov 7.
8
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
J Clin Oncol. 2022 Sep 10;40(26):3065-3076. doi: 10.1200/JCO.21.01926. Epub 2022 Apr 20.
9
Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension.
Cardiol Ther. 2021 Dec;10(2):397-406. doi: 10.1007/s40119-021-00233-7. Epub 2021 Jul 12.
10
Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis.
N Engl J Med. 2021 Apr 29;384(17):1601-1612. doi: 10.1056/NEJMoa2025956.
Zotero 插件